Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Obexelimab by Zenas BioPharma (USA) for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval
Obexelimab is under clinical development by Zenas BioPharma (USA) and currently in Phase III for Acquired (Autoimmune) Hemolytic Anemia. According...
Obexelimab by Zenas BioPharma (USA) for Immunoglobulin G4-Related Disease (IgG4-RD): Likelihood of Approval
Obexelimab is under clinical development by Zenas BioPharma (USA) and currently in Phase III for Immunoglobulin G4-Related Disease (IgG4-RD). According...
Obexelimab by Zenas BioPharma (USA) for Multiple Sclerosis: Likelihood of Approval
Obexelimab is under clinical development by Zenas BioPharma (USA) and currently in Phase II for Multiple Sclerosis. According to GlobalData,...